ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN ...

The European Bank for Reconstruction and Development (EBRD) and ELICA INTERCONNECTOR S.M. S.A., a company of Copelouzos Group, signed a grant agreement on Wednesday to fund the first studies for ...

On April 11, 2025, President Donald J. Trump underwent his annual physical examination at Walter Reed National Military Medical Center. I performed and supervised the comprehensive exam, which ...

Immunologists break down the options for treating seasonal allergies depending on symptoms and severity. They share the most effective treatment and one to avoid.

President Trump is in "excellent health," the White House physician said in a release following the president's annual physical at Walter Reed National Military Medical Center.

Actor brothers, Liam, left and Chris Hemsworth are both 6'3". Getty Images . Trump named Barbabella, a Navy physician with a degree in osteopathic medicine, as his personal physician last month.

The results from President Donald Trump's first physical exam of his second presidential term have been released after he was evaluated by White House physician Sean Barbabella at the Walter Reed ...

President Trump is in “excellent health,” his physician wrote in a memo released by the White House on Sunday after Trump underwent an annual physical exam. Trump underwent a heart exam, a ...

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, issued another. This time it’s for just shy of 1.5 million bottles of the ...

Overview: Topical mometasone is used to treat skin conditions that involve inflammation and itchiness. Common side effects from topical mometasone are skin reactions, such as redness, pain, and ...

Method for treating allergic rhinitis with mometasone and olopatadine. Source: United States Patent and Trademark Office (USPTO). Credit: Glenmark Pharmaceuticals Ltd. The patent US12064442B2 outlines ...

ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210, a bioabsorbable sinonasal implant (7500µg mometasone furoate), as a six-month treatment for chronic rhinosinusitis (CRS).